KOL Insight: Epilepsy [2020]

Maximum Purchase:
1 unit
Publication Date:
May 2020
Licence Type:
Multi-user licence
Adding to cart… The item has been added

Therapy Trends KOL Insight: Epilepsy

Why, despite regulatory setbacks, do KOLs consider Zogenix's Fintepla to be highly promising for Dravet syndrome? How do KOLs think safety concerns could be addressed with SK Life Science/Arvelle Therapeutics' Xcopri? Why do experts say Greenwich Biosciences/GW Pharmaceuticals' Epidiolex/Epidyolex needs to demonstrate utility beyond Dravet Syndrome and LGS to achieve substantial growth? US and European KOLs critically assess the prospects of launched and pipeline therapies.

Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk

Key questions answered

  • What is limiting uptake of advanced sodium channel blockers such as Sunovion/BIAL/Eisai's Aptiom/Zebinix and UCB's Vimpat?
  • Will UCB's Nayzilam and Neurelis' Valtoco intranasally administered therapies shape future treatment and how could Aquestive Therapeutics' buccally administered Libervant fit in?
  • Why do KOLs consider Marinus Pharmaceuticals' ganaxolone to be an attractive candidate for the treatment of refractory status epilepticus?
  • What lessons do KOLs have for Eisai as the use of their broad-spectrum AED drug Fycompa expands?

Examples of Therapies Covered

Vimpat Xcopri
Briviact Gabitril
Fycompa Felbatol
Fintepla Padsevonil
Ganaxolone Soticlestat
Aptiom/Zebinix Sabril/Kigabeq

Partial List of Participating KOLs

  • Professor of Pediatric Neurology
    The University of Tennessee Health Science Center, Memphis, TN
  • Professor of Neurology
    Mayo Clinic in Rochester, MN
  • Professor of Clinical Pharmacology
    University of Pavia, Pavia, Italy
  • Full Professor
    University of Leuven, Leuven, Belgium
  • Professor of Neurology
    UCLA David Geffen School of Medicine, Los Angeles, CA.
  • Full Professor
    Robert Debré University Hospital and Paris-Diderot University, Paris, France
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Job Title*
Company Name *
Country Name *
Job Function
Account Owner